Steve is the founder and executive director of OmTerra. OmTerra is a forming non-profit created to help foster the promotion, education and outreach for psychedelic therapy. Steve was also a participant in the UW-Madison FDA Pharmacokinetics study for psilocybin.
TITLE: High Dose Psilocybin and The Screaming Abyss: Journey to the Hell Realms in an FDA Clinical Study
As a participant in the 2015 FDA Approved Pharmacokinetics Study of Psilocybin at UW-Madison I went through three high-dose sessions with pure, crystallized psilocybin (29 mg, 44 mg and 59 mg) over three months. These three doses, over three months, doses took me to levels of hell and suffering that pushed the limits of human endurance. This presentation will recount the experience and the necessity of proper guidance when exploring high dose states. There will be additional discussion on the therapeutic significance of the “dark side” of high dose psychedelic therapy sessions with references to Stanislav Grof’s work with the Second Perinatal Matrix. This presentation also will discuss the myth of the bad trip in a therapeutic setting and the need to address the persisting effects questionnaire currently used in all psilocybin studies to subjectively measure the quality of the experience.